B7-H3 and PD-L1 Expression Are Prognostic Biomarkers in a Multi-racial Cohort of Patients with Colorectal Cancer
- 19 February 2021
- journal article
- research article
- Published by Elsevier BV in Clinical Colorectal Cancer
- Vol. 20 (2), 161-169
- https://doi.org/10.1016/j.clcc.2021.02.002
Abstract
No abstract availableKeywords
Funding Information
- National Institutes of Health (5R21AG058027-02, 1S10OD019961-01, P30CA013330)
- National Cancer Institute (5R21AG058027-02, 1S10OD019961-01, P30CA013330)
This publication has 29 references indexed in Scilit:
- Molecular Pathways: Targeting B7-H3 (CD276) for Human Cancer ImmunotherapyClinical Cancer Research, 2016
- Immune Checkpoint Blockade in Cancer TherapyJAMA, 2015
- PD-1 Blockade in Tumors with Mismatch-Repair DeficiencyThe New England Journal of Medicine, 2015
- Expression, Clinical Significance, and Receptor Identification of the Newest B7 Family Member HHLA2 ProteinClinical Cancer Research, 2015
- Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathwayTrends in Molecular Medicine, 2014
- Overexpression of B7-H3 in CD133+ colorectal cancer cells is associated with cancer progression and survival in human patientsJournal of Surgical Research, 2014
- HHLA2 is a member of the B7 family and inhibits human CD4 and CD8 T-cell functionProceedings of the National Academy of Sciences of the United States of America, 2013
- B7‐H3 expression in colorectal cancer: Nuclear localization strongly predicts poor outcome in colon cancerInternational Journal of Cancer, 2012
- Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomasPathology - Research and Practice, 2011
- Racial disparities in colorectal cancer survivalCancer, 2010